Amnoid - General Information
Amnoid is a novel synthetic retinoid for acute promyelocytic leukaemia (APL). Amnoid is currently approved in Japan for treatment of recurrent APL, and is undergoing clinical trials in the United States.
Pharmacology of Amnoid
Amnoid is a new synthetic retinoid drug recently approved for relapsed or refractory acute promyelocytic leukemia (APL) in Japan. It is a specific agonist for retinoic acid receptor alpha/beta. Compared to all-trans retinoic acid (ATRA), a natural retinoid indicated for a first-line treatment of APL, tamibarotene is chemically more stable and several times more potent as an inducer of differentiation in promyelocytic leukemia cells. In contrast to ATRA, whose plasma concentration declines considerably during daily administration, tamibarotene sustains plasma level probably due to a lower affinity for cellular retinoic acid binding protein. Furthermore, adverse side effects were milder than those of ATRA in clinical trials.
Additional information about Amnoid
Amnoid Indication: Investigated for use/treatment in leukemia (unspecified).
Mechanism Of Action: Amnoid is a specific agonist for retinoic acid receptor alpha/beta.
Drug Interactions: Not Available
Food Interactions: Not Available
Generic Name: Tamibarotene
Synonyms: Am 80; retinobenzoic acid
Drug Category: Anticancer Agents
Drug Type: Small Molecule; Approved; Investigational
Other Brand Names containing Tamibarotene: Amnoid; Tamibaro;
Absorption: Not Available
Toxicity (Overdose): Not Available
Protein Binding: Over 99%, predominantly to serum albumin.
Biotransformation: Not Available
Half Life: Not Available
Dosage Forms of Amnoid: Not Available
Chemical IUPAC Name: 4-[(5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)carbamoyl]benzoic acid
Chemical Formula: C22H25NO3
Tamibarotene on Wikipedia: Not Available
Organisms Affected: Humans and other mammals